Literature DB >> 29492808

Immunogenicity of adenovirus and DNA vaccines co-expressing P39 and lumazine synthase proteins of Brucella abortus in BALB/c mice.

Guo-Zhen Lin1,2, Ju-Tian Yang2, Suo-Cheng Wei2, Shi-En Chen2, Sheng-Dong Huo2, Zhong-Ren Ma3.   

Abstract

Brucella poses a great threat to animal and human health. Vaccination is the most promising strategy in the effort to control Brucella abortus (B. abortus) infection, but the currently used live vaccines interfere with diagnostic tests and could potentially result in disease outbreak. Therefore, new subunit vaccines and combined immunization strategies are currently under investigation. In this study, immunogenicity and protection ability of a recombinant adenovirus and plasmid DNA vaccine co-expressing P39 and lumazine synthase proteins of B. abortus were evaluated based on the construction of the two molecular vaccines. Four immunization strategies (single adenovirus, single DNA, adenovirus/DNA, DNA/adenovirus) were investigated. The results showed that the immunization strategy of DNA priming followed by adenovirus boosting induced robust humoral and cellular immune responses, and it significantly reduced the numbers of B. abortus in a mouse model. These results suggest that it could be a potential antigen candidate for development of a new subunit vaccine against B. abortus infection.

Entities:  

Keywords:  Adenovirus vaccine; BALB/c mice; Brucella abortus; DNA vaccine; Immunogenicity; Lumazine synthase; P39

Mesh:

Substances:

Year:  2018        PMID: 29492808     DOI: 10.1007/s11250-018-1517-7

Source DB:  PubMed          Journal:  Trop Anim Health Prod        ISSN: 0049-4747            Impact factor:   1.559


  26 in total

1.  Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of Brucella abortus in BALB/c mice.

Authors:  Shikha Jain; Prachiti Afley; Sudhir K Dohre; Nandita Saxena; Subodh Kumar
Journal:  Vaccine       Date:  2014-06-17       Impact factor: 3.641

2.  Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Joseph P Balint; Stephanie Balcaitis; Brigitte Sanders-Beer; Frank R Jones
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

3.  Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen.

Authors:  Maryam Golshani; Sima Rafati; Seyed Davar Siadat; Mehdi Nejati-Moheimani; Fereshteh Shahcheraghi; Amin Arsang; Saeid Bouzari
Journal:  Mol Immunol       Date:  2015-05-18       Impact factor: 4.407

4.  Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella.

Authors:  Zhongpeng Zhao; Min Li; Deyan Luo; Li Xing; Shuo Wu; Yueqiang Duan; Penghui Yang; Xiliang Wang
Journal:  Vaccine       Date:  2009-07-09       Impact factor: 3.641

Review 5.  Brucellosis: a re-emerging zoonosis.

Authors:  Mohamed N Seleem; Stephen M Boyle; Nammalwar Sriranganathan
Journal:  Vet Microbiol       Date:  2009-06-21       Impact factor: 3.293

6.  Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Laura Bruno; Silvia M Estein; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Clin Vaccine Immunol       Date:  2007-04-11

7.  Immunogenicity and protective efficacy of Brucella abortus recombinant protein cocktail (rOmp19+rP39) against B. abortus 544 and B. melitensis 16M infection in murine model.

Authors:  Ganesh Tadepalli; Amit Kumar Singh; Konduru Balakrishna; Harishchandra Sripathy Murali; Harsh Vardhan Batra
Journal:  Mol Immunol       Date:  2016-01-27       Impact factor: 4.407

8.  Immunogenicity Analysis of a Novel Subunit Vaccine Candidate Molecule-Recombinant L7/L12 Ribosomal Protein of Brucella suis.

Authors:  Zhi-Qiang Du; Xin Li; Jian-Ying Wang
Journal:  Appl Biochem Biotechnol       Date:  2016-04-13       Impact factor: 2.926

9.  Brucellosis: review on the recent trends in pathogenicity and laboratory diagnosis.

Authors:  Supriya Christopher; B L Umapathy; K L Ravikumar
Journal:  J Lab Physicians       Date:  2010-07

10.  Comparison between Immunization Routes of Live Attenuated Salmonella Typhimurium Strains Expressing BCSP31, Omp3b, and SOD of Brucella abortus in Murine Model.

Authors:  Won K Kim; Ja Y Moon; Suk Kim; Jin Hur
Journal:  Front Microbiol       Date:  2016-04-20       Impact factor: 5.640

View more
  3 in total

1.  Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing Brucella Immunodominant Proteins in Mice and Guinea Pigs.

Authors:  Dina Bugybayeva; Sholpan Ryskeldinova; Nadezhda Zinina; Makhpal Sarmykova; Nurika Assanzhanova; Zhailaubay Kydyrbayev; Kaissar Tabynov
Journal:  Biomed Res Int       Date:  2020-11-19       Impact factor: 3.411

2.  Effective gene therapy of Stargardt disease with PEG-ECO/pGRK1-ABCA4-S/MAR nanoparticles.

Authors:  Da Sun; Wenyu Sun; Song-Qi Gao; Jonathan Lehrer; Amirreza Naderi; Cheng Wei; Sangjoon Lee; Andrew L Schilb; Josef Scheidt; Ryan C Hall; Elias I Traboulsi; Krzysztof Palczewski; Zheng-Rong Lu
Journal:  Mol Ther Nucleic Acids       Date:  2022-08-24       Impact factor: 10.183

Review 3.  Evaluation of Brucellosis Vaccines: A Comprehensive Review.

Authors:  Mohsen Heidary; Shirin Dashtbin; Roya Ghanavati; Marzie Mahdizade Ari; Narjess Bostanghadiri; Atieh Darbandi; Tahereh Navidifar; Malihe Talebi
Journal:  Front Vet Sci       Date:  2022-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.